This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignees: Jiangsu Hengrui Pharmaceuticals Co., Ltd., Shanghai Senhui Medicine Co., Ltd., Shanghai Shengdi Pharmaceutical Co., Ltd.. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2026
Title: Bangjie Dong: Innovator in Benzazepine Compounds
Introduction
Bangjie Dong is a notable inventor based in Shanghai, China. He has made significant contributions to the field of pharmaceuticals, particularly through his innovative work on benzazepine compounds. His research focuses on the preparation methods and pharmaceutical applications of these compounds, which are essential in treating various health conditions.
Latest Patents
Bangjie Dong holds a patent for "Benzazepine compounds, preparation method therefor and pharmaceutical use thereof." This invention relates to a compound represented by formula II-1 or formula VIII-1, along with a pharmaceutical composition containing the same. The benzazepine compounds developed by Dong can be utilized for treating diseases associated with vasopressin receptors, specifically hypertension and heart disease. He has 1 patent to his name.
Career Highlights
Throughout his career, Bangjie Dong has worked with prominent companies in the pharmaceutical industry. He has been associated with Shanghai Senhui Medicine Co., Ltd. and Shanghai Shengdi Pharmaceutical Co., Ltd. His work in these organizations has contributed to advancements in medical treatments and drug development.
Collaborations
Some of his notable coworkers include Lingjian Zhu and Jianyu Shi. Their collaborative efforts have further enhanced the research and development of pharmaceutical innovations.
Conclusion
Bangjie Dong's contributions to the field of pharmaceuticals, particularly through his work on benzazepine compounds, highlight his role as an influential inventor. His research continues to impact the treatment of critical health issues, showcasing the importance of innovation in medicine.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile